October 5, 2017
FDA issues Safety Alert for intraocular TMV injections
Editor's Note
The Food & Drug Administration (FDA) on October 3 issued a Safety Alert saying the agency had received an adverse event report on a patient who was diagnosed with bilateral hemorrhagic occlusive retinal vasculitis after being administered injections of a compounded triamcinolone, moxifloxacin, vancomycin (TMV) formulation in each eye at the end of cataract surgery procedures that were done 2 weeks apart.
The TMV formulation was compounded by Imprimis Pharmaceuticals (Ledgewood, New Jersey).
Free Daily News
- Suicide Prevention Month: Hospitals prepare for new The Joint Commission suicide prevention goal, effective 2026
- Survey: Perioperative leaders adapt to supply strain, staffing pressure, ASC growth
- Gait retraining eases knee osteoarthritis pain as effectively as medication, can delay knee surgery
- OR leaders must sharpen questions, partnerships as AI reshapes perioperative care
- npj Digital Surgery opens call for research on AI, robotics in the OR
- AI in the OR can sharpen skills, but humans make the lessons stick
- Endoscopy case highlights risks of complex patients in ASCs
- Robotics and AI are redefining precision in cataract surgery
- CMS plan to phase out inpatient only list sparks debate over safety for vulnerable patients
- ACS issues new best practices for managing genitourinary trauma
© Access Intelligence, LLC. All rights reserved. |
Privacy Policy |
Cookie Settings |
Diversity, Equity, Inclusion & Belonging |
Accessibility Statement